ArticleCurrent microbiology2025
Isolation, Genomic Taxonomy, and Genome Characterization of Streptomyces fradiae SS162, Which has Antibacterial Activity Against Vibrio parahaemolyticus.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biocontrol of Vibrio parahaemolyticus, a pathogen responsible for acute hepatopancreatic necrosis disease (AHPND) in shrimp, has gained attention as an alternative to antibiotics in aquaculture. In this study, a bacterial strain isolated from a coral sample was preliminarily identified as Streptomyces sp. SS162 through 16S rRNA analysis exhibiting potent antibacterial activity with a high selectivity index against V. parahaemolyticus. This activity remained stable under high temperatures, various pH conditions, UV exposure, and proteinase K treatment. Furthermore, SS162 effectively inhibited biofilm formation by V. parahaemolyticus. Strain SS162 maintained the antibacterial activity over ten consecutive generations. For genomic taxonomy and characterization, a high-quality draft genome of 6,778,597 bp for the SS162 strain was obtained using next-generation sequencing with Nanopore technology. This genome had a GC content of 74.5% and contained 5,761 protein-coding genes. The genome of Streptomyces sp. SS162 possessed 23 subsystems belonging to 24 categories revealed by the RAST system. Comparative genomic analysis using Orthovenn3 indicated that SS162 shared the highest number of gene clusters with Streptomyces fradiae ATCC 10475. The genome phylogeny and relatedness analyses suggested that Streptomyces sp. SS162 was a strain within the Streptomyces fradiae species. Importantly, AntiSMASH analysis identified 28 biosynthetic gene clusters (BGCs), many of which were predicted to produce novel secondary metabolites. The remarkable in vitro activity against V. parahaemolyticus prompted further studies employing S. fradiae SS162 for AHPND management, whereas its taxonomic characterization and BGC identification confirmed the identity and uncovered the biotechnological potential in this strain.
Indexed as
Identifiers
40768039What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.